Interventions for Treating Collagenous Colitis

The quality of evidence isi downgraded by study quality and imprecise results.

A Cochrane review [Abstract] 1 included 12 studies with a total of 476 subjects with active collagenous colitis. These studies assessed bismuth subsalicylate, Boswellia serrata extract, mesalamine, cholestyramine, probiotics, prednisolone and budesonide therapy.

Low quality evidence suggests that budesonide may be effective for inducing and maintaining clinical and histological response in patients with collagenous colitis. Clinical response occurred in 80% (24/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study; 55 participants; RR 1.82, 95% CI 1.13 to 2.93). Histological response was observed in 87% (26/30) of budesonide patients compared to 44% (11/25) of mesalamine patients (1 study, 55 participants; RR 1.97, 95% CI 1.24 to 3.13). The benefits and harms of therapy with bismuth subsalicylate, Boswellia serrata extract, mesalamine with or without cholestyramine, prednisolone and probiotics are uncertain.

References

• Kafil TS, Nguyen TM, Patton PH et al. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2017;(11):CD003575. [PubMed]